Bristol-Myers Squibb Korea said that it has appointed Kim Jin-young as the new CEO and president of the newly merged company between BMS Korea and Celgene Korea. BMS completed the $74-billion acquisition of Celgene on Nov. 21.
|Bristol-Myers Squibb Korea CEO Kim Jin-young|
Kim has been serving as the interim CEO of the company since the resignation of BMS’s previous CEO, Park Hye-seon, in May.
Before her appointment, Kim worked at the legal department of Pfizer Korea and served as the general manager for the legal and compliance department at BMS offshoots in Korea, Taiwan, Thailand and Singapore.
“BMS is preparing to leap forward to become a leading biopharmaceutical company that changes the lives of patients through science, starting with the merger with Celgene,” the company said in a press release. “We will continue to work to realize the mission of discovering, developing, and delivering more innovative therapies to patients suffering from a serious illness.”
<© Korea Biomedical Review, All rights reserved.>